Q2 2026 revenue surged 48% to $22.97B, led by Mounjaro and Zepbound, with net income up 25% to $7.10B. Cardiometabolic products drove 65% of H1 revenue, while major acquisitions and manufacturing expansion supported growth. Pricing pressures and regulatory changes remain key risks.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.